COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02923804
Recruitment Status : Completed
First Posted : October 5, 2016
Last Update Posted : April 4, 2018
Nutrasource Diagnostics Inc.
Information provided by (Responsible Party):
Pronova BioPharma

Brief Summary:
This study is a prospective, randomized, placebo-controlled, double-blind trial to determine the effect of high concentrate omega-3 capsules on the omega-3 status of patients with non-alcoholic fatty liver.

Condition or disease Intervention/treatment Phase
Non Alcoholic Fatty Liver Dietary Supplement: Omega-3 Dietary Supplement: Olive oil Not Applicable

Detailed Description:
Subjects with non-alcoholic fatty liver (simple steatosis) confirmed within the last year by ultrasound or other imaging modality will be recruited to the study. Subjects will be randomized to a treatment arm of high concentrate capsules or placebo for a 6 month treatment period.Omega-3 content of red blood cells (omega-3 index) will be measured for primary endpoint assessment. Quantitative MRI will be performed to determine the effect on liver fat content.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 172 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care
Study Start Date : October 2015
Actual Primary Completion Date : December 1, 2017
Actual Study Completion Date : December 1, 2017

Arm Intervention/treatment
Experimental: Omega-3
3 capsules of 1g concentrated omega-3 taken daily for 6 months
Dietary Supplement: Omega-3
3x 1g capsules taken daily for 6 months

Placebo Comparator: Olive oil
3 capsules of 1g olive oil taken daily for 6 months
Dietary Supplement: Olive oil
3x 1g capsules taken daily for 6 months

Primary Outcome Measures :
  1. • The primary endpoint is the difference in mean percent changes from baseline (Week 24 each with baseline subtracted) between placebo and omega-3 groups [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. • Difference in mean percent change from baseline to end-of-treatment in RBC EPA and RBC DHA (percentage of lipids and quantitative measurements) [ Time Frame: 6 months ]
  2. • Difference in mean percent change from baseline to end of treatment in omega-6: omega-3 ratios. [ Time Frame: 6 months ]
  3. To assess the impact of omega-3 on changes in liver fat as determined by MRI-PDFF [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented history of clinical diagnosis of NAFLD by ultrasound, MRI or biopsy within one (1) year prior to screening (V1). If the diagnostic test date is greater than one (1) year, abdominal ultrasound will be repeated at (V1) and must confirm a diagnosis of NAFLD.
  2. Men or women, ≥18 years of age.
  3. BMI between 18.0 and 39.9 kg/m2.
  4. Non-smokers (>3 months of non-smoking).
  5. If on a statin regimen, history (> 1 month stable dose) of taking a statin medication (HMG-CoA reductase inhibitor example: Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo, etc).
  6. Able to understand and cooperate with study procedures, and have signed a written informed consent prior to any study procedures.

Exclusion Criteria:

  1. Diagnosis of NASH.
  2. Bilirubin >2x ULN.
  3. Other causes of liver inflammation including Hepatitis A, B or C, HIV, confirmed or suspected cirrhosis, Wilson's disease, autoimmune hepatitis, hemochromatosis, alcoholic steatohepatitis, pancreatitis, or prescription medications known to cause liver damage, or known to be hepatotoxic.
  4. Subjects with a history of bariatric surgery.
  5. Significant weight loss (> 5% body weight) or rapid weight loss (>1.6 kg/week), within six months of screening.
  6. Current or recent (within six months of screening) history of significant gastrointestinal, renal, pulmonary, hepatic or biliary disease, endocrine diseases or other invasive weight loss treatments (Type II Diabetes permitted, and stable (> 3 months) thyroid disorders).
  7. Individual taking prescription or over-the-counter medications (including dietary supplements, see Appendix 1) known to alter lipid metabolism, within four (4) weeks of randomization. These medications include (but are not limited to) the following: bile acid sequestrants, cholesterol absorption inhibitors, niacin or fibrates,
  8. Individuals taking prescription omega-3 fatty acids.
  9. Use of supplements including Omega-3s and Omega-6s, other oil-based supplements, phytosterols, Vitamin E, prebiotics and probiotics, or any weight loss supplements within four (4) weeks of randomization (multivitamins and minerals containing Vitamin E are permitted).
  10. Use of systemic corticosteroids, androgens (except androgens for hypogonadism to restore normal levels), phenytoin, erythromycin and other macrolides, thiazolidinediones (e.g. pioglitazone), and thyroid hormones (except stable-dose thyroid replacement therapy for four (4) weeks prior to enrollment).
  11. Use of the anticoagulants warfarin (Coumadin), dabigatran (Pradaxa), apixaban (Eliquis) or rivaroxaban (Xarelto). NOTE: Anti-platelet agents such as Plavix are allowed.
  12. Pregnant or lactating women or women of childbearing potential, who are not using an approved method of contraception. A woman is considered to be of childbearing potential unless she is post-hysterectomy, one or more years postmenopausal, or one or more years post-tubal ligation.
  13. History of significant cardiovascular or coronary heart disease (CVD or CHD) as defined by having had a coronary artery bypass procedure, coronary stent or angioplasty, or myocardial infarction in the previous six (6) months.
  14. History of cancer, other than non-melanoma skin cancer and basal cell carcinoma, within the previous five years.
  15. Poorly controlled or uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg).
  16. Recent history of prolonged alcohol (>3 months) use (within past 6 months) or excessive alcohol use, defined as >14 drinks per week (one drink = 12 oz. beer, 4 oz. wine, 1.5 oz. hard liquor).
  17. Exposure to any investigational agent within four (4) weeks prior to Visit 1.
  18. Subjects planning to undergo surgery during the study period or up to 1 month after the study
  19. Any serious psychiatric disease or disorder, which, in the opinion of the investigator, would preclude the subject from participating in the study.
  20. Any known intolerance to the investigational ingredients of this medical food.
  21. Has a condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk during the course of the study, including potentially abnormal lab results, due to a traumatic event.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02923804

Layout table for location information
United States, Florida
Hialeah, Florida, United States, 33012
Lake Worth
Lake Worth, Florida, United States, 33461
Lauderdale Lakes
Lauderdale Lakes, Florida, United States, 33319
Miami, Florida, United States, 33185
United States, South Carolina
Greenville, South Carolina, United States, 29615
United States, Texas
Arlington, Texas, United States, 76012
Arlington, Texas, United States, 76015
Sponsors and Collaborators
Pronova BioPharma
Nutrasource Diagnostics Inc.
Layout table for investigator information
Study Director: Derek Tobin, PhD BASF

Layout table for additonal information
Responsible Party: Pronova BioPharma Identifier: NCT02923804    
Other Study ID Numbers: 1051-001-PRO-19012015
First Posted: October 5, 2016    Key Record Dates
Last Update Posted: April 4, 2018
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Pronova BioPharma:
Polyunsaturated fatty acids
fish oil
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Nutrition Disorders